Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.12852 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of pharmacist-managed oncology ambulatory care for patients with non-small cell lung cancer in Taiwan.
J Food Drug Anal
December 2024
School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Non-small cell lung cancer (NSCLC) is commonly treated with tyrosine kinase inhibitors (TKIs). However, adverse events from such treatment can lead to treatment discontinuation and additional medical expenditures. Ambulatory care from oncology pharmacists in patient education and symptom management can benefit patients with NSCLC.
View Article and Find Full Text PDFPharmacist intervention and identification of adverse events related to treatment efficacy in cancer chemotherapy to improve clinical outcomes.
J Pharm Health Care Sci
December 2024
Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
Adverse events (AEs) induced by cancer chemotherapy reduce not only patient quality of life (QOL) but also the efficacy of treatment. Management of AEs can therefore improve both the efficacy and safety of cancer chemotherapy. This review describes the contribution of pharmacists to the management of adverse events aimed at improving the treatment efficacy of cancer chemotherapy.
View Article and Find Full Text PDFIntroduction: Targeted therapy has improved clinical outcomes for various types of cancer. However, their use is associated with dermatologic adverse events that impact quality of life and consistent therapies.
Objectives: The US Cutaneous Oncodermatology Management (USCOM) multidisciplinary-guided algorithm for preventing and managing cutaneous targeted therapy-related adverse events provides practical recommendations for cancer patients and survivors.
Effective Management of Severe Epidermal Growth Factor Receptor Inhibitors-Induced Papulopustular Eruption With Low-Dose Isotretinoin and Corticosteroids.
Cureus
November 2024
Oncologic Dermatology, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.
Epidermal growth factor receptor inhibitors (EGFRi) are approved for treating various cancers. Given that EGFR signaling is crucial for normal skin growth and repair, inhibiting this pathway can disrupt skin homeostasis and integrity. Although generally well tolerated, molecularly targeted therapies can lead to skin-related adverse effects that significantly impact patients' quality of life, often resulting in treatment interruptions.
View Article and Find Full Text PDFEGFR-TKIs induce acneiform rash and xerosis via Caspase-3/GSDME-mediated pyroptosis of keratinocytes and sebocytes.
Toxicology
November 2024
Department of Dermatology, Dermatology Hospital, Southern Medical University, No.2, Lujing Road, Yuexiu District, Guangzhou, Guangdong 510091, China. Electronic address:
Skin toxicities are the most common adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). While EGFR-TKIs induce pyroptosis in lung cancer cells through Gasdermin E (GSDME) activation, it is unknown whether they can similarly affect skin cells. In this study, we used immunohistochemistry to demonstrate that in acneiform rash, the N-terminus of GSDME (GSDME-N) is predominantly expressed in the basal layer of the follicular epithelium and sebocytes, while it is absent in the interfollicular epidermis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!